Cover Image
市場調查報告書

腹膜癌:開發中產品分析

Peritoneal Cancer - Pipeline Review, H2 2017

出版商 Global Markets Direct 商品編碼 229745
出版日期 內容資訊 英文 876 Pages
訂單完成後即時交付
價格
Back to Top
腹膜癌:開發中產品分析 Peritoneal Cancer - Pipeline Review, H2 2017
出版日期: 2017年10月10日 內容資訊: 英文 876 Pages
簡介

所謂腹膜癌是由腹膜發病的罕見癌症。腹膜是覆蓋於腹壁的薄膜,範圍廣及子宮到膀胱、直腸。腹膜癌一般會造成腹部腫脹、伴隨腹水的廣域性非特異性腹痛。常見的症狀有呼吸急促、直腸出血、食慾不振、頻尿、便秘、噁心、腹瀉,(即使只用輕食後)滿腹感等。主要的治療方法包含了化療、外科手術、生物學療法、放射線治療等。

本報告提供腹膜癌的治療藥開發情形調查分析,提供您開發中產品概要,臨床實驗的各階段產品概要,再加上主要企業簡介,藥物簡介,開發中產品的最新趨勢,最新消息和新聞稿等相關的系統性資訊。

簡介

  • 調查範圍

腹膜癌概要

治療藥的開發

  • 開發中產品的概要
  • 開發中產品比較分析

腹膜癌:企業開發中的治療藥

腹膜癌:大學/機關研究中的治療藥

腹膜癌:開發中產品概況

  • 後期階段的產品
  • 臨床階段的產品
  • 初期階段的產品

腹膜癌:企業開發中的產品

腹膜癌:大學/機關研究中的產品

腹膜癌的治療藥的開發企業

  • AbbVie Inc.
  • Acetylon Pharmaceuticals, Inc.
  • Adaptimmune Therapeutics Plc
  • Aduro BioTech, Inc.
  • Advanced Accelerator Applications SA
  • Advenchen Laboratories, LLC
  • Amgen Inc.
  • Array BioPharma Inc.
  • Astex Pharmaceuticals, Inc.
  • AstraZeneca Plc
  • Atara Biotherapeutics, Inc.
  • AVEO Pharmaceuticals, Inc.
  • Bayer AG
  • Boehringer Ingelheim GmbH
  • Boston Biomedical, Inc.
  • Caladrius Biosciences, Inc.
  • Celldex Therapeutics, Inc.
  • Celsion Corporation
  • CerRx, Inc.
  • Cerulean Pharma, Inc.
  • Clovis Oncology, Inc.
  • Corcept Therapeutics Incorporated
  • Critical Outcome Technologies Inc.
  • CritiTech, Inc.
  • CTI BioPharma Corp.
  • Dr. Reddy's Laboratories Limited
  • EirGenix Inc.
  • Eli Lilly and Company
  • Epirus Biopharmaceuticals, Inc.
  • Exelixis, Inc.
  • F. Hoffmann-La Roche Ltd.
  • Galena Biopharma, Inc.
  • Ganymed Pharmaceuticals AG
  • Genelux Corporation
  • Genentech, Inc.
  • Genor BioPharma Co., Ltd.
  • Glycotope GmbH
  • Gradalis Inc.
  • Hemispherx Biopharma, Inc.
  • ImmunoGen, Inc.
  • Immunovaccine, Inc.
  • Incyte Corporation
  • Innate Pharma S.A.
  • Johnson & Johnson
  • Juno Therapeutics Inc.
  • Kyowa Hakko Kirin
  • Lee's Pharmaceutical Holdings Limited
  • Mabion SA
  • MabVax Therapeutics Holdings, Inc.
  • MedImmune, LLC
  • Medivation, Inc.
  • Merck & Co., Inc.
  • Millennium Pharmaceuticals, Inc.
  • MolMed S.p.A.
  • Mycenax Biotech Inc.
  • Novartis AG
  • Oasmia Pharmaceutical AB
  • OBI Pharma, Inc.
  • Oncobiologics, Inc.
  • Oncolix, Inc.
  • Oncolytics Biotech Inc.
  • OncoMed Pharmaceuticals, Inc.
  • 小野藥品工業
  • Oxford BioMedica Plc
  • OXiGENE, Inc.
  • Pharma Mar, S.A.
  • Pharmacyclics, Inc.
  • PsiOxus Therapeutics Limited
  • Quest PharmaTech Inc.
  • Sanofi Pasteur SA
  • Shenzen SiBiono GeneTech Co., Ltd.
  • Sotio a.s.
  • Synta Pharmaceuticals Corp.
  • TapImmune Inc.
  • Tesaro, Inc.
  • TetraLogic Pharmaceuticals
  • Tyrogenex, Inc.
  • Vascular Biogenics Ltd.
  • VentiRx Pharmaceuticals, Inc.

腹膜癌:治療藥的評估

  • 單劑產品
  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介

腹膜癌:最近的開發平台趨勢

腹膜癌:暫停中的計劃

腹膜癌:開發中止的產品

腹膜癌:產品開發的里程碑

  • 主要消息和新聞稿

附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC9748IDB

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Peritoneal Cancer - Pipeline Review, H2 2017, provides an overview of the Peritoneal Cancer (Oncology) pipeline landscape.

Peritoneal cancer is a rare cancer that develops in the peritoneum, a thin, delicate sheet that lines the inside wall of the abdomen and covers the uterus and extends over the bladder and rectum. Peritoneal cancer usually manifests with abdominal distention and diffuse nonspecific abdominal pain secondary to ascites. Peritoneal cancer symptoms may include shortness of breath, rectal bleeding, loss of appetite, frequent urination, constipation, nausea or diarrhea and feeling of fullness, even after a light meal. Treatment includes options such as chemotherapy, surgery, biological therapy and radiation therapy.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Peritoneal Cancer - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Peritoneal Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Peritoneal Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Peritoneal Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 1, 2, 12, 63, 37, 17, 2 and 1 respectively. Similarly, the Universities portfolio in Phase II, Phase I and Preclinical stages comprises 2, 6 and 2 molecules, respectively.

Peritoneal Cancer (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Peritoneal Cancer (Oncology).
  • The pipeline guide reviews pipeline therapeutics for Peritoneal Cancer (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Peritoneal Cancer (Oncology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Peritoneal Cancer (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Peritoneal Cancer (Oncology)

Reasons to buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Peritoneal Cancer (Oncology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Peritoneal Cancer (Oncology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
  • Introduction
  • Peritoneal Cancer - Overview
  • Peritoneal Cancer - Therapeutics Development
  • Peritoneal Cancer - Therapeutics Assessment
  • Peritoneal Cancer - Companies Involved in Therapeutics Development
  • Peritoneal Cancer - Drug Profiles
  • Peritoneal Cancer - Dormant Projects
  • Peritoneal Cancer - Discontinued Products
  • Peritoneal Cancer - Product Development Milestones
  • Appendix

List of Tables

  • Number of Products under Development for Peritoneal Cancer, H2 2017
  • Number of Products under Development by Companies, H2 2017
  • Number of Products under Development by Companies, H2 2017 (Contd..1), H2 2017
  • Number of Products under Development by Companies, H2 2017 (Contd..2), H2 2017
  • Number of Products under Development by Companies, H2 2017 (Contd..3), H2 2017
  • Number of Products under Development by Companies, H2 2017 (Contd..4), H2 2017
  • Number of Products under Development by Companies, H2 2017 (Contd..5), H2 2017
  • Number of Products under Development by Universities/Institutes, H2 2017
  • Products under Development by Companies, H2 2017
  • Products under Development by Companies, H2 2017 (Contd..1), H2 2017
  • Products under Development by Companies, H2 2017 (Contd..2), H2 2017
  • Products under Development by Companies, H2 2017 (Contd..3), H2 2017
  • Products under Development by Companies, H2 2017 (Contd..4), H2 2017
  • Products under Development by Companies, H2 2017 (Contd..5), H2 2017
  • Products under Development by Companies, H2 2017 (Contd..6), H2 2017
  • Products under Development by Companies, H2 2017 (Contd..7), H2 2017
  • Products under Development by Universities/Institutes, H2 2017
  • Number of Products by Stage and Target, H2 2017
  • Number of Products by Stage and Target, H2 2017 (Contd..1), H2 2017
  • Number of Products by Stage and Target, H2 2017 (Contd..2), H2 2017
  • Number of Products by Stage and Target, H2 2017 (Contd..3), H2 2017
  • Number of Products by Stage and Target, H2 2017 (Contd..4), H2 2017
  • Number of Products by Stage and Target, H2 2017 (Contd..5), H2 2017
  • Number of Products by Stage and Mechanism of Action, H2 2017
  • Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..1), H2 2017
  • Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..2), H2 2017
  • Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..3), H2 2017
  • Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..4), H2 2017
  • Number of Products by Stage and Route of Administration, H2 2017
  • Number of Products by Stage and Molecule Type, H2 2017
  • Peritoneal Cancer - Pipeline by 3-V Biosciences Inc, H2 2017
  • Peritoneal Cancer - Pipeline by AbbVie Inc, H2 2017
  • Peritoneal Cancer - Pipeline by Adaptimmune Therapeutics Plc, H2 2017
  • Peritoneal Cancer - Pipeline by Aduro BioTech Inc, H2 2017
  • Peritoneal Cancer - Pipeline by Advenchen Laboratories LLC, H2 2017
  • Peritoneal Cancer - Pipeline by Altor BioScience Corp, H2 2017
  • Peritoneal Cancer - Pipeline by Amgen Inc, H2 2017
  • Peritoneal Cancer - Pipeline by Arrien Pharmaceuticals LLC, H2 2017
  • Peritoneal Cancer - Pipeline by Astellas Pharma Inc, H2 2017
  • Peritoneal Cancer - Pipeline by Astex Pharmaceuticals Inc, H2 2017
  • Peritoneal Cancer - Pipeline by AstraZeneca Plc, H2 2017
  • Peritoneal Cancer - Pipeline by Atara Biotherapeutics Inc, H2 2017
  • Peritoneal Cancer - Pipeline by AVEO Pharmaceuticals Inc, H2 2017
  • Peritoneal Cancer - Pipeline by Bayer AG, H2 2017
  • Peritoneal Cancer - Pipeline by BeiGene Ltd, H2 2017
  • Peritoneal Cancer - Pipeline by Boehringer Ingelheim GmbH, H2 2017
  • Peritoneal Cancer - Pipeline by Boston Biomedical Inc, H2 2017
  • Peritoneal Cancer - Pipeline by Bristol-Myers Squibb Co, H2 2017
  • Peritoneal Cancer - Pipeline by Celgene Corp, H2 2017
  • Peritoneal Cancer - Pipeline by Celldex Therapeutics Inc, H2 2017
  • Peritoneal Cancer - Pipeline by Celsion Corp, H2 2017
  • Peritoneal Cancer - Pipeline by CerRx Inc, H2 2017
  • Peritoneal Cancer - Pipeline by Chipscreen Biosciences Ltd, H2 2017
  • Peritoneal Cancer - Pipeline by Clovis Oncology Inc, H2 2017
  • Peritoneal Cancer - Pipeline by Critical Outcome Technologies Inc, H2 2017
  • Peritoneal Cancer - Pipeline by Dr. Reddy's Laboratories Ltd, H2 2017
  • Peritoneal Cancer - Pipeline by Eisai Co Ltd, H2 2017
  • Peritoneal Cancer - Pipeline by Eli Lilly and Co, H2 2017
  • Peritoneal Cancer - Pipeline by EpiThany Inc, H2 2017
  • Peritoneal Cancer - Pipeline by Exelixis Inc, H2 2017
  • Peritoneal Cancer - Pipeline by F. Hoffmann-La Roche Ltd, H2 2017
  • Peritoneal Cancer - Pipeline by Galena Biopharma Inc, H2 2017
  • Peritoneal Cancer - Pipeline by Gene Techno Science Co Ltd, H2 2017
  • Peritoneal Cancer - Pipeline by Genelux Corp, H2 2017
  • Peritoneal Cancer - Pipeline by Genentech Inc, H2 2017
  • Peritoneal Cancer - Pipeline by Genor BioPharma Co Ltd, H2 2017
  • Peritoneal Cancer - Pipeline by Glycotope GmbH, H2 2017
  • Peritoneal Cancer - Pipeline by Gradalis Inc, H2 2017
  • Peritoneal Cancer - Pipeline by Hemispherx Biopharma Inc, H2 2017
  • Peritoneal Cancer - Pipeline by ImmunoGen Inc, H2 2017
  • Peritoneal Cancer - Pipeline by Immunovaccine Inc, H2 2017
  • Peritoneal Cancer - Pipeline by Innate Immunotherapeutics Ltd, H2 2017
  • Peritoneal Cancer - Pipeline by Innate Pharma SA, H2 2017
  • Peritoneal Cancer - Pipeline by Jiangsu Hengrui Medicine Co Ltd, H2 2017
  • Peritoneal Cancer - Pipeline by Johnson & Johnson, H2 2017
  • Peritoneal Cancer - Pipeline by Juno Therapeutics Inc, H2 2017
  • Peritoneal Cancer - Pipeline by Kyowa Hakko Kirin Co Ltd, H2 2017
  • Peritoneal Cancer - Pipeline by Lidds AB, H2 2017
  • Peritoneal Cancer - Pipeline by Mabion SA, H2 2017
  • Peritoneal Cancer - Pipeline by MabVax Therapeutics Holdings Inc, H2 2017
  • Peritoneal Cancer - Pipeline by Madrigal Pharmaceuticals Inc., H2 2017
  • Peritoneal Cancer - Pipeline by MedImmune LLC, H2 2017
  • Peritoneal Cancer - Pipeline by Medivir AB, H2 2017
  • Peritoneal Cancer - Pipeline by Merck & Co Inc, H2 2017
  • Peritoneal Cancer - Pipeline by Merck KGaA, H2 2017
  • Peritoneal Cancer - Pipeline by Millennium Pharmaceuticals Inc, H2 2017
  • Peritoneal Cancer - Pipeline by MolMed SpA, H2 2017
  • Peritoneal Cancer - Pipeline by Mycenax Biotech Inc, H2 2017
  • Peritoneal Cancer - Pipeline by NewLink Genetics Corp, H2 2017
  • Peritoneal Cancer - Pipeline by Novartis AG, H2 2017
  • Peritoneal Cancer - Pipeline by Novogen Ltd, H2 2017
  • Peritoneal Cancer - Pipeline by Oasmia Pharmaceutical AB, H2 2017
  • Peritoneal Cancer - Pipeline by OBI Pharma Inc, H2 2017
  • Peritoneal Cancer - Pipeline by Oncobiologics Inc, H2 2017
  • Peritoneal Cancer - Pipeline by Oncolix Inc, H2 2017
  • Peritoneal Cancer - Pipeline by Oncolytics Biotech Inc, H2 2017
  • Peritoneal Cancer - Pipeline by OncoMed Pharmaceuticals Inc, H2 2017
  • Peritoneal Cancer - Pipeline by Ono Pharmaceutical Co Ltd, H2 2017
  • Peritoneal Cancer - Pipeline by Oxford BioMedica Plc, H2 2017
  • Peritoneal Cancer - Pipeline by Pfizer Inc, H2 2017
  • Peritoneal Cancer - Pipeline by Pharma Mar SA, H2 2017
  • Peritoneal Cancer - Pipeline by Polaris Pharmaceuticals Inc, H2 2017
  • Peritoneal Cancer - Pipeline by PsiOxus Therapeutics Ltd, H2 2017
  • Peritoneal Cancer - Pipeline by PTC Therapeutics Inc, H2 2017
  • Peritoneal Cancer - Pipeline by Richter Gedeon Nyrt, H2 2017
  • Peritoneal Cancer - Pipeline by Rigel Pharmaceuticals Inc, H2 2017
  • Peritoneal Cancer - Pipeline by Samyang Holdings Corp, H2 2017
  • Peritoneal Cancer - Pipeline by Sanofi, H2 2017
  • Peritoneal Cancer - Pipeline by Sanofi Pasteur SA, H2 2017
  • Peritoneal Cancer - Pipeline by Sotio AS, H2 2017
  • Peritoneal Cancer - Pipeline by Sun Pharma Advanced Research Company Ltd, H2 2017
  • Peritoneal Cancer - Pipeline by Syndax Pharmaceuticals Inc, H2 2017
  • Peritoneal Cancer - Pipeline by TapImmune Inc, H2 2017
  • Peritoneal Cancer - Pipeline by Tyrogenex Inc, H2 2017
  • Peritoneal Cancer - Pipeline by Vascular Biogenics Ltd, H2 2017
  • Peritoneal Cancer - Pipeline by Verastem Inc, H2 2017
  • Peritoneal Cancer - Pipeline by Vyriad Inc, H2 2017
  • Peritoneal Cancer - Dormant Projects, H2 2017
  • Peritoneal Cancer - Dormant Projects, H2 2017 (Contd..1), H2 2017
  • Peritoneal Cancer - Dormant Projects, H2 2017 (Contd..2), H2 2017
  • Peritoneal Cancer - Discontinued Products, H2 2017

List of Figures

  • Number of Products under Development for Peritoneal Cancer, H2 2017
  • Number of Products under Development by Companies, H2 2017
  • Number of Products under Development by Universities/Institutes, H2 2017
  • Number of Products by Top 10 Targets, H2 2017
  • Number of Products by Stage and Top 10 Targets, H2 2017
  • Number of Products by Top 10 Mechanism of Actions, H2 2017
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017
  • Number of Products by Top 10 Routes of Administration, H2 2017
  • Number of Products by Stage and Top 10 Routes of Administration, H2 2017
  • Number of Products by Top 10 Molecule Types, H2 2017
  • Number of Products by Stage and Top 10 Molecule Types, H2 2017
Back to Top